Devyser Genomic Laboratories signs first commercial agreement
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first...
Fetal RHD screening NIPT | January 17, 2024
Top performance at high-throughput: Devyser RHD maintains high sensitivity within an automated, high-throughput setting in Sahlgrenska University Hospital Study
Over the past decade, there has been a wealth of research investigating the ideal approach to RHD genotyping, to determine RhD incompatibility between mother and fetus, which is one of the main...
Find out more
